Pharmacological Management of Irritable Bowel Syndrome With Diarrhea
Summary of Recommendations
Eluxadoline
Rifaximin
Alosetron
Loperamide
TCAs
SSRIs
Antispasmodics
Video
Recommendation Grading
Disclaimer
Overview
Title
Pharmacological Management of Irritable Bowel Syndrome With Diarrhea
Authoring Organization
American Gastroenterological Association
Publication Month/Year
June 21, 2022
Supplemental Implementation Tools
Document Type
Guideline
Country of Publication
US
Document Objectives
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder associated with significant disease burden. This American Gastroenterological Association Guideline is intended to support practitioners in decisions about the use of medications for the pharmacological management of IBS with predominant diarrhea (IBS-D) and is an update of a prior technical review and guideline.
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Management
Diseases/Conditions (MeSH)
D043183 - Irritable Bowel Syndrome
Keywords
irritable bowel syndrome (IBS), IBS-D, IBS, irritable bowel syndrome with diarrhea
Source Citation
Lembo A, Sultan S, Chang L, et al. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology. 2022;163:137-151.